Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended Tuesday session in red amid volatile trading. The shares closed down -0.80 points or -1.59% at $49.47 with 6.10 million shares getting traded. Post opening the session at $50.06, the shares hit an intraday low of $49.30 and an intraday high of $50.57 and the price vacillated in this range throughout the day. The company has a market cap of $49.86 billion and the numbers of outstanding shares have been calculated to be 1.01 billion shares.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The companys Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The companys Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the womens health, oncology, and other specialty businesses.
Shares of Opko Health Inc. (NYSE:OPK) ended Tuesday session in green amid volatile trading. The shares closed up +0.13 points or 1.18% at $11.19 with 3.10 million shares getting traded. Post opening the session at $11.10, the shares hit an intraday low of $11.08 and an intraday high of $11.31 and the price vacillated in this range throughout the day. The company has a market cap of $6.29 billion and the numbers of outstanding shares have been calculated to be 550.38 million shares.
Opko Health Inc. (OPK) on September 27, 2016 announced the appointment of Benjamin D. Solomon, M.D. as Managing Director of GeneDx, effective as of October 3, 2016. GeneDx, part of OPKO’s BioReference Laboratories subsidiary, specializes in genetic testing for rare hereditary disorders.
Dr. Solomon is a pediatric geneticist who focuses on the use of genetics and genomics to identify, understand and care for patients with both rare and common genetic conditions. He is a leader in integrating cutting-edge technologies to better manage health and disease. He most recently served as Chief of the Division of Medical Genomics at the Inova Translational Medicine Institute, a clinical research institute dedicated to putting genomic medicine into action.
“We are very proud to have Dr. Solomon join the OPKO Health team as the new leader of our GeneDx division, a world-class genomics laboratory. A recognized leader in his field, Dr. Solomon’s expertise in genomics and genetics will be of great value as we continue to leverage leading technologies to build and expand GeneDx’s global role in diagnostic and laboratory services. His passion for finding answers for patients and clinicians and his talent and experience in the integration of genomics into the practice of medicine will enhance the numerous and diverse communities in the U.S. and worldwide that benefit from the outstanding diagnostic services our laboratories offer,” said Gregory S. Henderson, M.D., Ph.D., President of BioReference Laboratories.